GlassScriptPhysician profile
Horst P Knapp
NPI 1922059724
$15,116.35
in general payments reported to CMS, 2019-2025
35 companies · $2,400 in 2025
The $2,400 reported for 2025 was more than what 92% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,160 · 2020: $526 · 2021: $4,495 · 2022: $1,737 · 2023: $1,146 · 2024: $652 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726 · Travel and Lodging: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.85 |
| Travel and Lodging | $472.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $4,520.63 | 2019-2025 | |
| Arthrex, INC. | $3,214.22 | 2019-2021 | |
| Pylant Medical | $2,926.56 | 2019-2025 | |
| Stryker Corporation | $1,570.21 | 2019-2025 | Inbone, Salvation, Augment Injectable |
| Nevro Corp. | $496.37 | 2022-2023 | Senza |
| Horizon Therapeutics Plc | $410.60 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $307.58 | 2019-2025 | Grafix Pl, Stravix Pl, Collagenase Santyl |
| Pacira Pharmaceuticals Incorporated | $296.75 | 2019-2021 | |
| Depuy Synthes Sales INC. | $169.26 | 2019-2023 | Motoband |
| Orthofix Medical, INC. | $165.96 | 2019-2025 | Physio-Stim |
| Osteoremedies, LLC | $152.61 | 2025 | Xperience, Blastx |
| Paratek Pharmaceuticals, INC. | $134.84 | 2022-2023 | Nuzyra |
| Anika Therapeutics, INC. | $117.09 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.93 | 2019-2023 | Jublia |
| Ibsa Pharma INC. | $78.13 | 2022-2023 | Tirosint, Licart |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $60.60 | 2019-2022 | |
| Biotissue Holdings INC. | $32.95 | 2021-2024 | |
| Convatec INC. | $30.99 | 2025 | |
| Averitas Pharma INC. | $29.67 | 2024 | Qutenza |
| Glenmark Therapeutics INC. | $29.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.47 | 2019 | |
| Bsn Medical INC | $25.45 | 2019 | |
| Nabriva Therapeutics, Plc | $25.23 | 2021 | |
| Wright Medical Technology, INC. | $24.15 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.51 | 2025 | |
| Medline Industries LP | $20.52 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $17.22 | 2023 | Seglentis |
| Integra Lifesciences Corporation | $17.12 | 2019 | |
| Nvision Biomedical Technologies, INC. | $16.31 | 2024 | Trigon |
| Sebela Pharmaceuticals INC. | $15.15 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $13.79 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2019 | |
| Abbott Laboratories | $13.32 | 2019 | |
| Tactile Systems Technology INC | $12.35 | 2019 | |
| Amniox Medical, INC. | $9.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Horst Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.